FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.
Commentary|Slideshows|March 10, 2025
February's Special Report: Child and Adolescent Psychiatry
Discover key insights from February’s Special Report on child and adolescent psychiatry, exploring overlooked diagnoses, new research, and the complex impact of social media on youth mental health.
Advertisement
Advertisement
Related to this article
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Courts cite teen brain science to soften sentences; experts warn generalized neuroscience overreaches and adult responsibility stabilizes by 18 to 20.
Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement